Latest Shareholder Approvals News

Netlinkz Limited reports steady customer receipts and strategic investments in its Securelink joint venture, while preparing for an ASX relisting and a rebrand to Securelink Networks Ltd.

Belararox Limited has kicked off its 2025/26 field season in Argentina and progressed drilling in Botswana’s Kalahari Copper Belt, supported by a recent A$8.5 million capital raise that strengthens its financial position.

Breakthrough Minerals has entered a conditional agreement to acquire a substantial North Queensland Copper-Gold Project near Mt Isa, boasting an 18.8 million tonne resource and backed by an $8.15 million capital raise. The acquisition positions the company for aggressive exploration and development in a prolific copper district.

Locate Technologies has ended its Australian ATM Facility, initiated a new NZ$10 million facility in New Zealand, and proposed a share buy-back pending shareholder approval, aligning with its Bitcoin Treasury ambitions.

Peninsula Energy reported a $7.3 million operating cash outflow for Q3 2025, alongside securing a $12.6 million convertible debt facility to advance its Lance Project in Wyoming. The company ends the quarter with $36 million in cash, supporting an estimated six quarters of funding.

Biotron Limited has advanced its Hepatitis B antiviral program while preparing to acquire Sedarex Limited, backed by a $2.5 million capital raise. The move signals a strategic expansion into safer anaesthetics alongside ongoing R&D progress.

Beonic Limited has locked in a $7.3 million contract for its North African Airport Project following a successful proof of concept, while reporting improved gross margins and positive cash flow in Q1 FY26. The company also completed a $4.3 million capital raise to support growth and innovation.

Zenith Minerals has validated a large-scale gold system at its Red Mountain project and initiated its largest ever drilling campaign at Consolidated Dulcie, backed by a strong A$11.15 million capital raise.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Cann Group Limited has opened a $6.5 million Share Purchase Plan (SPP) alongside a placement, offering shareholders discounted shares with attaching options as it targets significant revenue growth in FY26.